Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$885.03 USD

885.03
1,163,785

-6.04 (-0.68%)

Updated Oct 3, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Procter & Gamble, Eli Lilly, Thermo Fisher Scientific, Costco Wholesale and Shopify

The Zacks Analyst Blog Highlights: Procter & Gamble, Eli Lilly, Thermo Fisher Scientific, Costco Wholesale and Shopify

Company News for Jun 17, 2020

Companies in the news are: WW, LLY, CLIR, CVU

Novartis' (NVS) Cosentyx Gets FDA Nod for New Indication

Novartis' (NVS) Cosentyx wins FDA approval for a fourth indication ??? active non-radiographic axial spondyloarthritis (nr-axSpA).

Lilly Gains as Verzenio Meets Early Breast Cancer Study Goal

Lilly's (LLY) phase III study on Verzenio in HR+, HER2- early breast cancer met its primary endpoint of invasive disease-free survival.

Lilly Begins Phase III Study on Olumiant for Coronavirus

Lilly's (LLY) Olumiant is being studied for COVID-19 on the assumption that JAK1 and JAK2 inhibition may reduce cytokine storm, a complication associated with COVID-19.

Sheraz Mian headshot

Top Analyst Reports for Procter & Gamble, Eli Lilly & Thermo Fisher

Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Eli Lilly (LLY) and Thermo Fisher Scientific (TMO).

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $141.52, marking a -1.41% move from the previous day.

Glaxo (GSK) HIV Drug Tivicay Gets FDA Approval for Toddlers

FDA approves Glaxo's (GSK) oral suspension formulation of its three-drug regimen for HIV, Tivicay, as a treatment for patients aged at least four weeks and weighing at least 3kg.

Merck's Gardasil Gets FDA Approval for Head and Neck Cancers

FDA grants accelerated approval for label expansion application of Merck's (MRK) human papillomavirus vaccine, Gardasil, to include oropharyngeal and other head and neck cancers.

This is Why Eli Lilly (LLY) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals

J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.

AbbVie Inks Deal With Genmab, Announces ADC Candidate Data

AbbVie (ABBV) signs deal with Genmab to jointly develop three early-stage bispecific antibody product candidates. Its novel ADC candidate, ABBV-3373 demonstrates clinical activity in study.

Pfizer's Eczema Candidate Meets All Goals in Study on Teens

Pfizer's (PFE) investigational eczema treatment, abrocitinib, succeeds in a late-stage study under the JADE program in patients aged 12 years and above.

Company News for Jun 11, 2020

Companies In The News Are: LLY, VRNT, SBUX, TCO, SPG.

ESG Investing Trend to Stay Strong Post Pandemic: 5 Top Picks

Investing in ESG stocks bear lesser financial risks due to their focus on environment, employees and supply chain. They proved resilient during the coronavirus pandemic and will continue to surge.

Lilly Begins Cardiovascular Outcomes Study on Tirzepatide

Lilly (LLY) announces that the first patient dose has been delivered in a cardiovascular outcome study on its novel diabetes candidate, tirzepatide.

Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I

Lilly (LLY) is set to study JS016 as a monotherapy and in combination with antibody treatments including LY-CoV555, its first potential COVID-19 antibody candidate that recently entered phase I.

Hexo Corp. (HEXO) to Post Q3 Earnings: What's in the Offing?

Hexo's (HEXO) fiscal third-quarter results are likely to reflect operational efficiency and strong product portfolio.

Eli Lilly (LLY) Flat As Market Gains: What You Should Know

In the latest trading session, Eli Lilly (LLY) closed at $149.21, marking no change from the previous day.

Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication

The FDA approves Merck's (MRK) sNDA seeking approval for its antibacterial injection Recarbrio regarding a new indication. The application was filed in February 2020.

Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

AstraZeneca's Calquence Shows Promise as Coronavirus Treatment

Peer-reviewed data on AstraZeneca's (AZN) Calquence shows that it improves laboratory markers of inflammation and decreases oxygen requirements in most patients hospitalized due to COVID-19.

Cooper Companies (COO) Misses on Q2 Earnings and Revenues

Cooper Companies' (COO) fiscal second-quarter earnings reflect dismal segmental performance and decline in revenues.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals

Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.

Novartis (NVS) Announces Positive Data From Cosentyx Study

Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.